ADMA Biologics, Inc. (ADMA)
NASDAQ: ADMA · Real-Time Price · USD
9.55
-0.03 (-0.31%)
Sep 4, 2026, 1:20 PM EDT - Market open
ADMA Biologics Revenue
ADMA Biologics had revenue of $124.40M in the quarter ending June 30, 2026, with 1.98% growth. This brings the company's revenue in the last twelve months to $512.28M, up 8.04% year-over-year. In the year 2025, ADMA Biologics had annual revenue of $510.17M with 19.63% growth.
Revenue (ttm)
$512.28M
Revenue Growth
+8.04%
P/S Ratio
4.13
Revenue / Employee
$791,770
Employees
647
Market Cap
2.14B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 510.17M | 83.72M | 19.63% |
| Dec 31, 2024 | 426.45M | 168.24M | 65.15% |
| Dec 31, 2023 | 258.22M | 104.14M | 67.59% |
| Dec 31, 2022 | 154.08M | 73.14M | 90.36% |
| Dec 31, 2021 | 80.94M | 38.72M | 91.72% |
| Dec 31, 2020 | 42.22M | 12.87M | 43.85% |
| Dec 31, 2019 | 29.35M | 12.36M | 72.79% |
| Dec 31, 2018 | 16.99M | -5.78M | -25.37% |
| Dec 31, 2017 | 22.76M | 12.10M | 113.49% |
| Dec 31, 2016 | 10.66M | 3.48M | 48.53% |
| Dec 31, 2015 | 7.18M | 1.26M | 21.34% |
| Dec 31, 2014 | 5.92M | 2.85M | 92.84% |
| Dec 31, 2013 | 3.07M | 1.95M | 174.35% |
| Dec 31, 2012 | 1.12M | 357.08K | 46.92% |
| Dec 31, 2011 | 761.04K | - | - |
| Jun 30, 2011 | - | - | - |
| Dec 31, 2010 | - | - | - |
| Jun 30, 2010 | - | - | - |
| Jun 30, 2009 | - | - | - |
| Jun 30, 2008 | - | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Aurinia Pharmaceuticals | 311.51M |
| Vericel | 306.30M |
| UroGen Pharma | 188.73M |
| Mesoblast | 120.25M |
| Zymeworks | 37.13M |
| Generate Biomedicines | 26.48M |
| Zenas BioPharma | 1.00M |
ADMA News
- 3 days ago - Berger Montague PC Investigates ADMA Biologics, Inc.'s Board of Directors for Breach of Fiduciary Duty (NASDAQ: ADMA) - PRNewsWire
- 11 days ago - Berger Montague PC Investigates ADMA Biologics, Inc.'s Board of Directors for Breach of Fiduciary Duty (ADMA) - Newsfile Corp
- 4 weeks ago - Adma Biologics reports Q2 EPS 16c, consensus 16c - TheFly
- 4 weeks ago - Adma Biologics backs FY26 revenue view $530M-$560M, consensus $534.37M - TheFly
- 4 weeks ago - ADMA Biologics Earnings Call Transcript: Q2 2026 - Transcripts
- 4 weeks ago - ADMA Biologics Earnings release: Q2 2026 - Filings
- 4 weeks ago - ADMA Biologics Quarterly report: Q2 2026 - Filings
- 4 weeks ago - ADMA Biologics Reports Second Quarter 2026 Financial Results and Provides Business Update - GlobeNewsWire